Ads
related to: what is aminoglycoside therapy for osteoporosis symptoms diet patient diagnosis
Search results
Results From The WOW.Com Content Network
Aminoglycosides can exacerbate weakness in patients with myasthenia gravis, and use is therefore avoided in these patients. [26] Aminoglycosides are contraindicated in patients with mitochondrial diseases as they may result in impaired mtDNA translation, which can lead to irreversible hearing loss, tinnitus, cardiac toxicity, and renal toxicity.
Senile osteoporosis has been recently recognized as a geriatric syndrome with a particular pathophysiology. There are different classification of osteoporosis: primary, in which bone loss is a result of aging and secondary, in which bone loss occurs from various clinical and lifestyle factors. [1]
It is clinically characterized by severe osteoporosis which is usually recognized and posteriorly diagnosed in early childhood. This usually leads to various complications, the primary one being recurrent bone fractures. [1] [2] Another very common symptom is total blindness, which usually manifests in two ways:
The International Osteoporosis Foundation and the European Calcified Tissue Society recommend pharmacological therapy for osteoporosis in postmenopausal women and men ≥70 years, with a previous fragility fracture, or a dose equivalent of prednisone ≥7.5 mg daily for ≥3 months. For premenopausal women and men <50 years taking steroids for ...
The uses of bisphosphonates include the prevention and treatment of osteoporosis, Paget's disease of bone, bone metastasis (with or without hypercalcemia), multiple myeloma, primary hyperparathyroidism, osteogenesis imperfecta, fibrous dysplasia, and other conditions that exhibit bone fragility.
Osteoporosis, a skeletal disorder characterized by compromised bone strength and increased risk of fractures, is a major concern in bone health, particularly among older adults. [ 2 ] [ 3 ] Maintaining good bone health involves a combination of adequate calcium and vitamin D intake, regular weight-bearing exercise, and avoiding risk factors ...
The US National Osteoporosis Foundation recommends pharmacologic treatment for patients with hip or spine fracture thought to be related to osteoporosis, those with BMD 2.5 SD or more below the young normal mean (T-score -2.5 or below), and those with BMD between 1 and 2.5 SD below normal mean whose 10-year risk, using FRAX, for hip fracture is ...
Treatment of osteoporosis or non-malignant bone disease with denosumab (not taking systemic glucocorticoids) High: Patients being treated for osteoporosis or non-malignant bone disease with oral bisphosphonates/quarterly or yearly infusions of intravenous bisphosphonates for >5 years